Arrhythmogenic Cardiomyopathy: Pharmacologic Management

Mark S. Link, N. A Mark Estes

Research output: Contribution to journalReview articlepeer-review


Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalCardiac Electrophysiology Clinics
Issue number2
StatePublished - Jun 2011


  • Antiarrhythmic agents
  • Arrhythmogenic right ventricular cardiomyopathy/dysplasia
  • Pharmacologic management
  • Therapy
  • β-Blocker

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Arrhythmogenic Cardiomyopathy: Pharmacologic Management'. Together they form a unique fingerprint.

Cite this